DiabetesVATC-SSNCT07734259
Voice-activated and Touchscreen-controlled Smart Speaker Intervention for Older Adults With Poorly Controlled Type 2 Diabetes
A study testing VATC-SS Intervention in people with Diabetes and Diabetes (DM), run by Medical College of Wisconsin.
Trial summary
This is a pre-post pilot study that will test the feasibility and acceptability of a health educator delivered diabetes education and skills training intervention using a voice-activated, touch screen controlled, smart speaker. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Diabetes, Diabetes (DM), Type 2 Diabetes
- What is being tested?
- VATC-SS Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 30 Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1) Aged 50 and older; 2) clinical diagnosis of poorly controlled type 2 diabetes, defined as HbA1C greater than or equal to 8% at the screening visit; 3) willing to install and use the VATC-SS for the 3 months of the study.
Who cannot join
- 1) Mental confusion at screening assessment suggesting significant dementia; 2) alcohol or drug abuse/dependency at screening assessment; 3) active psychosis or acute mental disorder at screening assessment.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This is a pre-post pilot study that will test the feasibility and acceptability of a health educator delivered diabetes education and skills training intervention using a voice-activated, touch screen controlled, smart speaker. We will enroll 30 adults aged 50 and older with poorly controlled type 2 diabetes as defined by a hemoglobin A1C of 8% in the study.
- Conditions
- Diabetes, Diabetes (DM), Type 2 Diabetes
- Being tested
- VATC-SS Intervention
- Medical subject headings
- Diabetes Mellitus, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VATC-SS InterventionBehavioural
Individuals in the VATC-SS intervention will receive weekly diabetes education and skills training calls for 12 weeks from a health educator through the voice-activated, touch screen controlled smart speaker.
| Study group | Role | What they receive |
|---|---|---|
| VATC-SS Intervention | Experimental | Individuals in the VATC-SS intervention will receive weekly diabetes education and skills training calls for 12 weeks from a health educator through the voice-activated, touch screen controlled smart speaker. Receives: Behavioral: VATC-SS Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
HemoglobinA1C
About 10cc of blood will be drawn by phlebotomist and sent to the lab for testing
Measured: Baseline and 3-months post enrollment
Blood Pressure
Blood pressure readings will be obtained using automated blood pressure monitors (OMRON IntelliSenseTM HEM-907 XL). The device will be programmed to take 3 readings at 2-minute intervals and give an average of the 3 blood pressure readings.
Measured: Baseline and 3-months post-enrollment
Low-Density Lipoprotein Cholesterol
About 10cc of blood will be drawn by phlebotomist and sent to the lab for testing
Measured: Baseline and 3-months post-enrollment
Secondary outcomes (3)
Depression
Depression will be measured using the 9-item Patient Health Questionnaire (PHQ-9)
Measured: Baseline and 3-months post-enrollment
Social Isolation
The PROMIS Short Form v2.0 - Social Isolation 8a will be used to measure social isolation
Measured: Baseline and 3-months post-enrollment
Loneliness
The five-item Loneliness Fixed form from the NIH Toolbox Item Bank v3.0 for adults will be used to assess loneliness
Measured: Baseline and 3-months post-enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2026
- Study start1 Sep 2026 (estimated)
- Primary completion30 Jan 2028 (estimated)
- Study completion30 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical College of Wisconsin
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aprill Z. Dawson, PhD, MPH, Medical College of Wisconsin
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07734259
- Sponsor's protocol ID
- PRO00058852
- Acronym
- VATC-SS
- Status last verified
- Jul 2026
- First submitted
- 24 Jul 2026
- Last updated
- 29 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Voice-activated and Touchscreen-controlled Smart Speaker Intervention for Older Adults With Poorly Controlled Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT07734259
- Acronym / sponsor ID
- VATC-SS / PRO00058852
- Conditions
- Diabetes, Diabetes (DM), Type 2 Diabetes
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Medical College of WisconsinUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 30 Jan 2028 (estimated)
- Study completion
- 30 Mar 2028 (estimated)
- First posted
- 29 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a pre-post pilot study that will test the feasibility and acceptability of a health educator delivered diabetes education and skills training intervention using a voice-activated, touch screen controlled, smart speaker. We will enroll 30 adults aged 50 and older with poorly controlled type 2 diabetes as defined by a hemoglobin A1C of 8% in the study.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| VATC-SS Intervention | Experimental | Behavioral: VATC-SS InterventionIndividuals in the VATC-SS intervention will receive weekly diabetes education and skills training calls for 12 weeks from a health educator through the voice-activated, touch screen controlled smart speaker. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- 1) Aged 50 and older; 2) clinical diagnosis of poorly controlled type 2 diabetes, defined as HbA1C greater than or equal to 8% at the screening visit; 3) willing to install and use the VATC-SS for the 3 months of the study.
Key exclusion criteria (1 listed)
- 1) Mental confusion at screening assessment suggesting significant dementia; 2) alcohol or drug abuse/dependency at screening assessment; 3) active psychosis or acute mental disorder at screening assessment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VATC-SS InterventionIndividuals in the VATC-SS intervention will receive weekly diabetes education and skills training calls for 12 weeks from a health educator through the voice-activated, touch screen controlled smart speaker. | Behavioural | VATC-SS Intervention |
Primary outcome
HemoglobinA1C
Time frame: Baseline and 3-months post enrollment
About 10cc of blood will be drawn by phlebotomist and sent to the lab for testing
Blood Pressure
Time frame: Baseline and 3-months post-enrollment
Blood pressure readings will be obtained using automated blood pressure monitors (OMRON IntelliSenseTM HEM-907 XL). The device will be programmed to take 3 readings at 2-minute intervals and give an average of the 3 blood pressure readings.
Low-Density Lipoprotein Cholesterol
Time frame: Baseline and 3-months post-enrollment
About 10cc of blood will be drawn by phlebotomist and sent to the lab for testing
3 secondary outcomes
Depression
Time frame: Baseline and 3-months post-enrollment
Social Isolation
Time frame: Baseline and 3-months post-enrollment
Loneliness
Time frame: Baseline and 3-months post-enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Diabetes
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 1/2
Vasopressin and Pain Perception in the Brain
Acute Pain
RecruitingPhase 4
INfluenza VaccInation To Mitigate typE 1 Diabetes
Diabetes Mellitus, Type 1
RecruitingPhase 4
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Type 1 Diabetes
RecruitingEarly Phase 1
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
Gestational Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing VATC-SS Intervention in people with Diabetes and Diabetes (DM), run by Medical College of Wisconsin.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aprill Z Dawson, PhD, MPH (414-955-8828, adawson@mcw.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HemoglobinA1C (time frame: Baseline and 3-months post enrollment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2026; AzTrials last refreshed its copy on 29 Oct 2026.